Concord Drugs Ltd. engages in the provision of pharmaceutical formulations. The company is headquartered in Hyderabad, Telangana. The company went IPO on 2015-02-23. The firm is engaged in manufacturing of licensed drugs based on the formulations approved. The firm offers finished pharmaceutical formulations, such as injectables (small volume parenteral, dry powders), tissue bio-adhesive, tablets, capsules, liquid orals (syrup & suspension) and dry syrups (powder). The firm also provides ready-to-fill pellets and multiple unit pellets system (MUPS). Its pellets are categorized as gastrointestinal drug pellets, cardiovascular drug pellets, respiratory drug pellets, anti-obesity drug pellets, anti-depressant drug pellets, central nervous system drug pellets, urological drug pellets, anti-microbial, anti-infective and adjuvant drugs pellets, taste mask drug pellets/powder, nutrition and food supplement drug pellets, anti-cholesterol drug pellets. The firm also provides Iso Amyl 2-Cyano Acrylate, which is a bio-adhesive product.
Loading chart…
Our models read the latest earnings call, annual report, and financials end-to-end - then grade management, value the business, and flag the risks. Unlock all of it for this company:
The headline call - descriptive label, conviction, and the synthesis behind it.
Guidance-anchored P&L bridge - worst / average / best multiple cases.
Did management deliver on past guidance? A commitment-by-commitment scorecard.
Forensic and governance risk pointers, severity-ranked.
Solvency and earnings-quality score.
Quarter-by-quarter earnings-call briefs - what changed and why.